HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $14.41, but opened at $15.14. HUTCHMED shares last traded at $15.10, with a volume of 13,427 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research report on Monday, November 18th.
View Our Latest Analysis on HUTCHMED
HUTCHMED Stock Performance
The business's fifty day simple moving average is $16.81 and its 200-day simple moving average is $17.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Investors Weigh In On HUTCHMED
A number of large investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio bought a new position in HUTCHMED in the third quarter worth about $35,000. Blue Trust Inc. grew its holdings in shares of HUTCHMED by 638.2% during the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after acquiring an additional 3,057 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company's stock worth $117,000 after acquiring an additional 2,321 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock valued at $129,000 after purchasing an additional 564 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of HUTCHMED during the second quarter valued at approximately $213,000. 8.82% of the stock is currently owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
